Bookmark and Share
peroxisome proliferator-activated receptor ga.. [gi:20336229] - Target BioActivity Data
Also known as: peroxisome proliferator-activated receptor gamma isoform 2 [Homo sapiens].
Filters: All Data » Active      
Filter selected
BioActivity Outcomes:
Probe(1)
 
 
Active(5141)
 
 
BioAssay Types:
Screening(3040)
 
 
Confirmatory(428)
 
 
Literature(164)
 
 
BioActivity Types:
EC50(225)
 
 
IC50(203)
 
 
Substance Types:
Chemical(5142)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 25    Data Row: 5142   Total Pages: 258   Display: Page     
Sort: [Click the result table header to sort]
#StructureSubstanceCompoundActivityBioAssayLinks
OutcomeTypeValue [μM]
1
[SID124349301]
[CID53239856]
Late stage assay provider counterscreen results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): chemiluminescence-based biochemical western blot assay for inhibitors of phosphorylation of PPARG protein levels [AID504938, Type: other]
View
2
[SID124349300]
IC50 0.00037Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
3
[SID104223102]
EC50 0.0005Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): Luminescence-based cell-based dose response assay to identify transactivation inhibitor of PPRE (PPARG response element) [AID504939, Type: confirmatory]
View
4
[SID104223102]
IC50 0.00054Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
5
[SID124349300]
EC50 0.00054Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): Luminescence-based cell-based dose response assay to identify transactivation inhibitor of PPRE (PPARG response element) [AID504939, Type: confirmatory]
View
6
[SID118043696]
EC50 0.002Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): Luminescence-based cell-based dose response assay to identify transactivation inhibitor of PPRE (PPARG response element) [AID504939, Type: confirmatory]
View
7
[SID118043696]
IC50 0.002Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
8
[SID104223105]
EC50 0.002Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): Luminescence-based cell-based dose response assay to identify transactivation inhibitor of PPRE (PPARG response element) [AID504939, Type: confirmatory]
View
9
[SID124349302]
IC50 0.004Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
10
[SID104223105]
IC50 0.006Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
11
[SID118043694]
IC50 0.006Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
12
[SID124349305]
EC50 0.021Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): Luminescence-based cell-based dose response assay to identify transactivation inhibitor of PPRE (PPARG response element) [AID504939, Type: confirmatory]
View
13
[SID124349303]
IC50 0.024Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
14
[SID124349305]
IC50 0.029Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
15
[SID22401659]
[CID1234827]
IC50 0.05552Counterscreen for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3): TR-FRET-based biochemical high throughput dose response assay to identify agonists of the interaction between peroxisome proliferator-activated receptor gamma (PPARg) and nuclear receptor co-repressor 2 (NCOR2) [AID2759, Type: confirmatory]
View
16
[SID124349301]
[CID53239856]
IC50 0.08Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): TR-FRET-based biochemical dose response competitive binding lanthascreen assay for non-agonists of the PPARg [AID504943, Type: confirmatory]
View
17
[SID118043694]
EC50 0.116Late stage assay provider results from the probe development effort to identify non-agonists of the peroxisome proliferator-activated receptor gamma (PPARg): Luminescence-based cell-based dose response assay to identify transactivation inhibitor of PPRE (PPARG response element) [AID504939, Type: confirmatory]
View
18
[SID91762765]
[CID1328217]
IC50 0.152Fluorescence-polarization-based biochemical polarscreen dose response binding assay for partial agonists of the peroxisome proliferator-activated receptor gamma (PPARg) [AID504453, Type: confirmatory]
View
19
[SID14746391]
[CID1262634]
IC50 0.15203Counterscreen for NR2E3 inverse agonists: TR-FRET-based biochemical high throughput dose response assay to identify inverse agonists of the interaction between peroxisome proliferator-activated receptor gamma (PPARg) and nuclear receptor co-repressor 2 (NCOR2) [AID463257, Type: confirmatory]
View
20
[SID91762729]
[CID3442864]
IC50 0.173Fluorescence-polarization-based biochemical polarscreen dose response binding assay for partial agonists of the peroxisome proliferator-activated receptor gamma (PPARg) [AID504453, Type: confirmatory]
View